Dok1 and Dok2 proteins regulate natural killer cell development and function by Celis‐Gutierrez, Javier et al.
Article
Dok1 and Dok2 proteins regulate natural killer cell
development and function
Javier Celis-Gutierrez1,2,3,4, Marilyn Boyron4,5,6,†, Thierry Walzer4,5,6,7,†, Pier Paolo Pandolfi8,
Stipan Jonjic9, Daniel Olive1,2,3,4, Marc Dalod4,5,6, Eric Vivier4,5,6,10 & Jacques A Nunès1,2,3,4,*
Abstract
Natural killer (NK) cells are involved in immune responses against
tumors and microbes. NK-cell activation is regulated by intrinsic
and extrinsic mechanisms that ensure NK tolerance and efficacy.
Here, we show that the cytoplasmic signaling molecules Dok1
and Dok2 are tyrosine phosphorylated upon NK-cell activation.
Overexpression of Dok proteins in human NK cells reduces cell
activation induced by NK-cell-activating receptors. Dok1 and Dok2
gene ablation in mice induces an NK-cell maturation defect and
leads to increased IFN-c production induced by activating recep-
tors. Taken together, these results reveal that Dok1 and Dok2
proteins are involved in an intrinsic negative feedback loop down-
stream of NK-cell-activating receptors in mouse and human.
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Introduction
Natural killer (NK) cells are innate lymphocytes that participate in
the first line of defense against tumors or microbe-infected cells.
Targeting NK-cell receptors represents an attractive therapeutic
strategy for the treatment of cancers (Ljunggren & Malmberg, 2007;
Vey et al, 2012; Zitvogel et al, 2008). Understanding the mecha-
nisms underlying NK-cell maturation and function may improve the
design of clinical trials (Vivier et al, 2012).
Engagement of activating and inhibitory NK-cell receptors trig-
gers intracellular signals that regulate NK-cell cytokine production
and cytotoxicity (Long et al, 2013; Vivier et al, 2004). A first level of
regulation of these signals occurs via the engagement of protein
tyrosine kinases (PTK) downstream of activating NK receptors and
protein tyrosine phosphatases (PTP) downstream of inhibitory
receptors. This control of cytoplasmic protein tyrosine phosphoryla-
tion of key signaling elements such as Vav-1 is critical to transduce
functional signals in NK cells. More recently, non-enzymatic adaptor
proteins that are PTK substrates, such as Crk, have also been
involved in the regulation of both activation and inhibition of NK
cells (Liu et al, 2012). Crk tyrosine phosphorylation induced by
inhibitory receptors shuts down the activation signals. Among the
negative adaptor proteins known to be expressed in leukocytes, the
group of Dok (downstream of tyrosine kinase) proteins, Dok1,
Dok2, and Dok3, is involved in T- and B-cell signaling (Mashima
et al, 2009). Here, we report that DOK1 and DOK2 genes are
expressed in both human and mouse NK cells. During T-cell activa-
tion, Dok1 and Dok2 proteins are tyrosine phosphorylated (Dong
et al, 2006; Nemorin et al, 2001; Nunes et al, 1996). Dok1 and
Dok2 overexpression in T cells decreases IL-2 production in acti-
vated cells (Gerard et al, 2004; Guittard et al, 2009; Nemorin et al,
2001), and loss or reduction of Dok1 and Dok2 expression in
primary T cells enhances TCR-mediated functions and signaling
(Dong et al, 2006; Yasuda et al, 2007). While most studies show
that Dok1 and Dok2 act as negative regulators in leukocytes (Mashima
et al, 2009), there is also evidence that these signaling molecules
are involved in positive regulation of leukocyte signaling (Inoue
et al, 2007; Lee et al, 2012).
Here, we provide evidence that Dok1 and Dok2 are tyrosine
phosphorylated upon engagement of activating receptors in NK
cells. Dok1 and Dok2 act as negative feedback regulators of NK
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activation signals in human NK cells. In addition, NK-cell develop-
ment is impaired in Dok1-/Dok2-deficient (DKO) mice. Remarkably,
experiments in these mice reveal that Dok1 and Dok2 downregulate
NK-cell activation induced by NK-cell-activating receptors, but upre-
gulate cell activation induced by IL-12 and IL-18. This differential
impact on NK-cell-activating pathways provides new insights into
regulation of NK-cell effector function.
Results
Dok1 and Dok2 proteins are substrates of protein tyrosine
kinases in NK cells
Dok family members are involved in immune cell signaling; however,
their expression in NK cells has not been investigated (Mashima
et al, 2009). DOK1 and especially DOK2 transcripts are expressed in
both human and mouse NK cells. Other DOK genes appear not to be
expressed in NK cells (Supplementary Fig S1). Dok1 and Dok2 can be
detected in primary NK cells and human NK-cell lines by immunoblot
(Fig 1A). To test whether Dok1/2 are PTK substrates in NK cells, the
human NK-cell lines KHYG-1 and NKL were stimulated with antibod-
ies against the NKp30, NKG2D, or 2B4 activating NK-cell-surface
receptors (Fig 1B, Supplementary Fig S2), then Dok immunoprecipi-
tates were revealed by anti-phosphotyrosine immunoblots. Dok1 was
tyrosine phosphorylated upon NKp30, NKG2D, or 2B4 triggering, but
not following cross-linking of the CD94/NKG2A inhibitory receptor
(Fig 1B, Supplementary Fig S2). As for Dok1, Dok2 tyrosine phos-
phorylation was also detected in KHYG-1 cells (data not shown). The
level of NKp30-induced Dok1 tyrosine phosphorylation decreased
upon co-engagement of NKp30 and CD94/NKG2A (Fig 1B), suggest-
ing that DOK1/2 are substrates of the SHP-1/2 protein tyrosine phos-
phatases reported to be associated with the CD94/NKG2A inhibitory
receptor signaling (Le Drean et al, 1998).
Dok proteins act as negative feedback regulators of activating
NK-cell receptor signaling
In T cells, Dok1 and Dok2 proteins are mostly involved in negative
regulation of TCR-induced T-cell activation (Acuto et al, 2008;
Gerard et al, 2004). By recruiting enzymes transducing negative
signals such as Ras GTPase-activating protein (RasGAP) and SH2
(Src homology 2)-containing inositol phosphatase-1 (SHIP1), Dok1
and Dok2 inhibit Ras/ERK and PI3K/Akt signaling pathways (Acuto
et al, 2008; Mashima et al, 2009). To investigate the role of these
signaling molecules in NK-cell signaling, we transfected the human
NK-cell line KHYG-1 with GFP-tagged Dok2 either full-length or
deleted of its pleckstrin homology (PH) domain (DPH-Dok2, a loss-
of-function mutant of Dok2) (Guittard et al, 2009). Following NKp30
triggering, tyrosine phosphorylation of full-length Dok2 but not of
DPH-Dok2 was detected (Fig 2A). The level of NKp30-induced ERK
or AKT phosphorylation was reduced when full-length Dok2 was
overexpressed. This inhibitory effect was not detected with the Dok2
loss-of-function version DPH-Dok2. The results show that Dok2
overexpression in NK cells inhibits cell signaling induced by NKp30.
We then investigated the role of Dok1 and Dok2 in NK-cell effec-
tor function. KHYG-1 cells transfected with full-length or PH-deleted
Dok1/Dok2 were stimulated with anti-NKp30 Ab for 4–5 h, and
their production of IFN-c was measured by flow cytometry (Fig 2B).
Dok1 or Dok2 overexpression decreased NKp30-induced IFN-c
production. As a control, both DPH-Dok1 and DPH-Dok2 loss-of-
function mutants did not alter IFN-c production. Next, we measured
the cytolytic activity of KHYG-1 transfected cells against K562
human tumor cells using a standard 4 h 51Cr release assay (Fig 2C).
Both for Dok1 (left panel) and Dok2 (right panel), the full-length
form was more efficient than the DPH-Dok loss-of-function mutants
to reduce NK-cell cytotoxicity. Altogether, these results demonstrate
that Dok1 and Dok2 signaling molecules are negative regulators of
NK-cell function in human cells.
Dok1 and Dok2 function in NK-cell maturation
Dok1 and Dok2 genes are expressed in mouse NK cells (Supplemen-
tary Fig S1B). As Dok1 and Dok2 have overlapping functions and
A
B
Figure 1. Dok1 and Dok2 are substrates of protein tyrosine kinases upon
ITAM receptors triggering in NK cells.
A Whole-cell lysates (WCL) from primary human NK cells and NK lines were
separated by SDS–PAGE and immunoblotted for Dok1 and Dok2 proteins.
Protein bands identified at molecular weight of 62 and 56 kDa correspond
to Dok1 and Dok2 proteins, respectively. WCL from primary NK cells and
KHYG-1 cell line were treated separately of the other WCLs. Human tumor
cell lines, HUT-78 (T-cell lymphoma) and HeLa (cervical cancer), known to
express or not Dok1/Dok2 proteins were included as positive and negative
controls, respectively. This experiment is representative of three
independent experiments.
B KHYG-1 cells, IL-2-starved for at least 18 h, were incubated with either
anti-NKp30 or anti-NKG2A Abs (alone or in combination) and then
stimulated by cross-linking with goat anti-mouse F(ab’)2 at 37°C for
indicated times. After stimulation, NKL cells were lysed and lysates were
immunoprecipitated with an anti-Dok1 Ab, resolved on SDS–PAGE and
immunoblotted for anti-phosphotyrosine mAb (clone 4G10). A fraction from
WCL was immunoblotted for phospho-ERK1/2 and then reprobed for total
ERK1/2. This experiment is representative of two independent experiments.
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Figure 2. Dok1 and Dok2 negatively regulate the NK-cell signaling and function triggered by ITAM receptors.
A KHYG-1 cells were transfected by nucleofection with plasmids encoding for GFP-tagged full-length (FL) Dok2, its mutant lacking the PH domain, DPHDok2-GFP, or
GFP alone. KHYG-1 cells were then stimulated by Ab-mediated cross-linking using a mouse anti-NKp30 Ab and a goat anti-mouse F(ab’)2 Ab at 37°C for indicated
times. Finally, KHYG-1 cells were lysed and lysates were immunoprecipitated using an anti-GFP Ab followed by SDS–PAGE and anti-phosphotyrosine immunoblot
allowing the identification of phospho-Dok2. In parallel, WCL were separated by SDS–PAGE and subsequently immunoblotted for phosphoSer473-Akt and phospho-
ERK1/2. The blots were reprobed for total Akt and ERK1/2. This panel shows representative blots of at least three independent experiments.
B, C KHYG-1 cells expressing GFP-tagged Dok1 or Dok2 full-length (FL) proteins or lacking the PH domain (DPH) were stimulated with plate-bound anti-NKp30 mAb
during 4-5 h and then stained for IFN-c production (B) or were incubated with K562 target cells at different E:T ratios to analyze NK-cell cytotoxicity activity in
a 4-h 51Cr release assay (C). Significant differences are detected between cells transfected with the empty vector (mock) and plasmid encoding for Dok proteins
(FL); **P < 0.001; *P < 0.05.
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single Dok1- or Dok2-deficient mice did not show obvious pheno-
types (Mashima et al, 2009), we thus used mice deficient for both
Dok1 and Dok2 (DKO) mice, to investigate the role of Dok1 and
Dok2 in NK cells. The absolute and relative number of NK cells in
several organs such as spleen, lymph nodes, blood, and liver was
decreased in DKO mice as compared to WT mice (Fig 3A–C). The
percentage of NK cells was however normal in the BM of DKO mice
(Fig 3C). Heterozygous Dok1+/Dok2+/ mice showed an inter-
mediate phenotype, suggesting a dosage-dependent effect of DOK
proteins. These results show that Dok1-/Dok2-deficient mice display
reduced numbers of peripheral NK cells.
NK-cell development mainly occurs in the BM (Di Santo &
Vosshenrich, 2006). Precursors committed to the NK-cell lineage
express the c-subunit of IL-2/IL-15 receptor, CD122, and lack other
lineage markers. Subsequently, these precursors reach an immature
NK-cell phenotype, characterized by the sequential acquisition of
NK receptor expression at the cell surface, such as NK1.1, NKp46,
CD94-NKG2, and Ly49. NK cells then upregulate the CD11b b2 inte-
grin, as well as CD43 and KLRG-1, cell surface molecules that
define the mature NK-cell phenotype (Kim et al, 2002; Narni-
Mancinelli et al, 2011). Monitoring CD11b and CD27 expression on
NK-cell surface allows the classification of NK-cell maturation
A
B
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Figure 3. Reduced numbers of peripheral NK cells in Dok1-/Dok2-deficient mice.
Analysis by flow cytometry of lymphocyte populations isolated from various organs of Dok1-/Dok2-deficient (DKO), wild-type (WT), and heterozygous (WT × DKO = DKO+/)
129/Sv mice and stained for CD3 and NKp46.
A Percentage and absolute numbers of CD3 NKp46+ NK cells in spleen from WT and DKO 129/Sv mice. Each plot represents the data obtained from 1 mouse.
***P < 0.0001; **P < 0.01.
B, C The percentage of CD3 NKp46+ NK cells resident in different organs has been analyzed from the three types of mice (WT, DKO+/,and DKO). (B) Gating is shown
for the spleen. (C) Histograms corresponding to the NK-cell frequency for the indicated organs  SD (n = 9–20 mice, depending on the organ).
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in three sequential stages, namely CD27highCD11blow (immature),
CD27highCD11bhigh (semi-mature), and CD27lowCD11bhigh (mature)
(Chiossone et al, 2009; Hayakawa & Smyth, 2006). We studied the
impact of the absence of Dok1 and Dok2 on the maturation status
of NK cells in various lymphoid compartments (Fig 4A and B). A
significant accumulation of immature CD27highCD11blow NK cells
and a corresponding reduction of mature CD27lowCD11bhigh cells
were observed in the lymphoid organs of DKO mice as compared
with WT mice. Moreover, we measured the expression of the termi-
nal differentiation markers CD43 and KLRG-1 on CD27lowCD11bhigh
NK cells (Fig 4C). A block in the NK transition from
CD27highCD11bhighKLRG-1low toward the CD27lowCD11bhighKLRG-
1high stage was observed in the BM or spleen from DKO versus WT
mice (Fig 4C, left panel). Similar results were obtained using CD43
as a marker of terminal NK-cell differentiation (Fig 4C, right panel).
Again, heterozygous mice displayed an intermediate phenotype.
Altogether, these results demonstrate a role of Dok1/Dok2 in the
maturation of NK cells.
Dok1-/Dok2-deficient NK cells present an intrinsic
developmental defect
The impaired NK-cell development observed in Dok1-/Dok2-defi-
cient mice could be due to a role of Dok proteins in NK cells or in
their environment. To discriminate between these possibilities, we
generated mixed BM chimeric mice by reconstituting lethally irradi-
ated C57BL/6 (CD45.1+) mice with a 1:1 mix of BM from C57BL/6
CD45.1+ and 129/Sv CD45.2+ mice or C57BL/6 CD45.1+ and DKO
(CD45.2+) mice. Eight to ten weeks after reconstitution, we
measured the percentages of NK cells within CD45.2+ cells and their
maturation status in each BM chimera type. The percentage of NK
cells within CD45.2 cells was significantly reduced in C57BL/6:DKO
chimera mice as compared to C57BL/6:129/Sv chimera mice
(Fig 5A). This defect was accompanied by a significant reduction of
the mature CD27low CD11bhigh NK-cell subset and thus an increased
frequency of the CD27high CD11blow cell subset through all exam-
ined organs (Fig 5B). These observations indicate that the impair-
ment of NK development in Dok1-/Dok2-deficient mice is due to an
intrinsic NK-cell defect.
The reduced frequency of NK cells and mostly of mature NK cells
in DKO mice could be accounted for by different cellular mecha-
nisms, such as increased apoptosis. To test this hypothesis, we
analyzed NK cell death ex vivo in overnight culture of splenocytes
from WT and DKO mice gating on CD11bhigh NK-cell subset
(Fig 5C). DKO mice displayed higher levels of apoptotic and dead
CD11bhigh NK cells as compared to WT mice according to the
Annexin V and 7-AAD stainings. Moreover, overnight culture with
anti-apoptotic IL-15 cytokine weakly rescued DKO CD11bhigh NK
cells from cell death (Fig 5C). Altogether, these results suggest that
the reduced frequency of mature NK cells could be due to a high
rate of cell apoptosis in this subset.
Loss of Dok1 and Dok2 induces the upregulation of IFN-c
production downstream of NK receptor stimulation
We then tested the role of Dok1/2 in mouse NK-cell effector func-
tion. Resting or in vivo poly(I:C)-primed NK cells were stimulated
in vitro using mAb-mediated cross-linking of activation receptors or
using IL-12 alone or in combination with IL-2 or IL-18. A higher
proportion of DKO CD11bhigh NK cells produced IFN-c upon Ly49D
receptor cross-linking as compared to WT CD11bhigh NK cells. Simi-
larly, incubation with YAC-1 tumor cells and cytokine stimulation
(IL-12 and IL-12/IL-2) induced a higher IFN-c response in DKO NK
cells versus WT NK cells. In contrast, upon stimulation with IL-12
plus IL-18, a strong synergistic stimulus for IFN-c production, DKO
CD11bhigh NK cells produced less IFN-c as compared to WT NK cells
(Fig 6B, right panel; Supplementary Fig S3). In vivo poly(I:C) priming
significantly increased NK responsiveness in both groups, but did not
change the differences detected between DKO and WT CD11bhigh NK
cells (Fig 6B). These data indicate that Dok1/Dok2 proteins inhibit
IFN-c production induced by NK-cell-activating receptors, but
increase IFN-c production induced by IL-12 and IL-18 receptors.
Upon NKp46 triggering with saturating mAb concentrations, a
similar IFN-c expression was detected in WT and DKO NK cells
(Fig 6A and B, right panel). But, with lower concentrations of the
NKp46 agonistic mAb (2.5 lg/ml instead of 10 lg/ml), a difference
in IFN-c production in CD11bhigh NK cells was observed between
WT and DKO mice (Fig 6C). At low doses of stimuli, IFN-c produc-
tion was higher in CD11bhigh DKO NK cells than in CD11bhigh WT
NK cells. Similar observations were made with a Ly49D mAb
titration (Supplementary Fig S5A). Thus, Dok1 and Dok2 proteins
are negative regulators of NK-cell response downstream of NK-cell-
activating receptors.
Dok1 and Dok2 proteins are involved in the negative regulation
of the Ras/ERK-1/2 and PI3K/AKT pathways (Mashima et al, 2009,
Fig 2A). To assess whether Dok1 and Dok2 fulfill the same function
in mouse NK cells, we performed phosphoflow analysis for two
phosphoproteins, AKT and ERK-1/2 on CD11bhigh NK cells from WT
and DKO mice following engagement of NKp46 (Fig 6D, Supplemen-
tary Fig S4). The engagement of NKp46 at low doses of cross-linking
mAb triggered higher AKT and ERK phosphorylation levels in DKO
than in WT NK cells (Fig 6D). However, when doses of cross-linking
mAbs reached saturation levels, the AKT and ERK phosphorylation
levels were similar to those detected in WT CD11bhigh NK cells.
Similar results were obtained with anti-Ly49D mAb stimulation
(Supplementary Fig S5B). Hence, Dok1/Dok2 adaptors are able to
negatively regulate NK-cell-activating signaling pathways, leading in
turn to a decrease in IFN-c secretion.
Control of MCMV infection in Dok1-/Dok2-deficient mice
NK cells are involved in the early control of viral infections induced
by the mouse cytomegalovirus (MCMV), both through IFN-c
Figure 4. Dok1-/Dok2-deficient NK cells show a developmental blockade in the last stages.
A Flow cytometry analysis of bone marrow (BM)-resident and splenic NK-cell subsets according to CD27 and CD11b staining as: CD27High/CD11bLow (immature);
CD27High/CD11bHigh (semi-immature); and CD27Low/CD11bHigh (mature) in WT, DKO+/. and DKO mice.
B The numbers in the panels represent the frequency  SD of each NK subset of the indicated organs from WT, DKO+/, and DKO mice (n = 9–20). ***P < 0.0001;
**P < 0.01, and *P < 0.05 (one-way ANOVA test).
C The histograms shown correspond to the expression of CD27 and CD43 markers in gated CD11bHigh NK-cell population from BM and spleen of WT, DKO+/, and DKO
mice. This experiment is representative of four independent experiments.
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production and through killing of infected cells (Loh et al, 2005),
provided that the combination of the mouse and virus strains used
allows NK-cell recognition of, activation by, and killing of infected
cells (Miletic et al, 2013). In C57BL/6 mice, NK cell-mediated resis-
tance against MCMV infection is naturally allowed by the interaction
between the activating NK receptor Ly49H and its virally encoded
ligand m157 (Arase et al, 2002; Smith et al, 2002). In 129 strains
infected by WT viruses, NK cells are activated but fail to control
viral replication due to the absence on infected cells of a proper
ligand able to trigger NK-cell-activating receptors. However, this
situation can be overcome by using a virus strain (Dm152Rae1c
MCMV) engineered to promote a strong expression of NKG2D
ligands on the surface of infected cells (Slavuljica et al, 2010),
enabling the study of in vivo NK-cell reactivity during a viral infec-
tion in our 129/Sv background DKO mice. We inoculated DKO and
WT 129/Sv mice with Dm152Rae1c MCMV and measured viral
titers in the spleen and liver, and NK-cell activation in the spleen at
different time points after infection. MCMV replication was identical
at d1.5 and d2 post-infection in both mouse strains (partially shown
in Fig 7B). However, at d3 post-infection, MCMV titers were still
high in DKO mice, while WT animals had already controlled the
infection (Fig 7A and B). The plaque assay also shows a trend
toward lower viral loads in the spleen of DKO mice at day 3 post-
infection although it did not reach significance. This enhanced
susceptibility of DKO mice to MCMV infection was only transient,
since the mice had achieved complete control of MCMV replication
by day 6 under our experimental conditions (Fig 7B). The propor-
tion of mature, CD11b+, NK cells was lower in the spleen of DKO
mice at all time points examined (Fig 7C and not shown). However,
no other difference in NK-cell activation could be detected between
DKO and WT animals at any of the time points tested, in terms of
IFN-c (Fig 7D) and granzyme B expression (Fig 7E), proliferation as
measured by Ki-67 intracellular staining, apoptosis as measured by
7-AAD staining, and NKG2D expression (data not shown). Of note,
no deficit in the production of IFN-b and in the induction of its
downstream target gene Mx1 was observed in MCMV-infected DKO
mice, ruling out a deficit of myeloid or infected cells in the induction
of the antiviral type I interferons responses in these animals
(Supplementary Fig S6). Although the NK-cell numbers are strongly
decreased in the DKO mice under steady-state conditions, NK cells
accumulate in the spleen upon MCMV infection in both WT and
DKO animals to reach high levels similar between the two mouse
strains between days 3 and 6 which may correlate with the delayed
but ultimately similar ability of DKO mice to control viral replica-
tion. Thus, these results show that Dok1/Dok2 proteins are neces-
sary to promote early control of MCMV replication, potentially in
part by promoting the constitution of a pool of mature CD11b+ NK
cells able to more rapidly control viral replication.
Discussion
In the present study, we identified two members of the Dok adaptor
proteins, Dok1 and Dok2, as substrates of protein tyrosine kinases
upon engagement of NK-cell-activating receptors. To determine the
role of these proteins in NK cells, experiments were performed both
in human NK-cell lines by overexpressing wild-type or transdomi-
nant negative forms of Dok1 or Dok2, and in Dok1/Dok2 DKO mice.
Dok1 and Dok2 negatively regulate NK-cell activation induced by
the engagement of NK-cell-activating receptors in both mice and
humans. These results are consistent with those described in other
immune cell types, such as T cells (Acuto et al, 2008; Mashima et al,
2009). Dok proteins thus act as negative feedback loops downstream
of NK-cell-activating receptors. Therefore, in addition to the
regulation of activating NK-cell receptors by their co-engagement
with inhibitory ITIM-bearing receptors (Long et al, 2013; Vivier
et al, 2004), we described here another negative checkpoint that
controls NK-cell-activating receptor signaling as an auto-regulatory
loop.
Combined deficiencies in both Dok1 and Dok2 impair NK-cell
development in vivo. There are less mature NK cells in the lymphoid
organs of DKO mice than in WT mice, and as demonstrated by data
obtained in mixed BM chimeras experiments, this defect is intrinsic
to the NK-cell compartment. Furthermore, DKO mice display higher
counts of dying mature NK cells as compared to WT mice,
suggesting that the Dok proteins regulate apoptosis during NK-cell
maturation.
Besides its negative regulatory function, Dok1 has been previ-
ously reported to act as a positive regulator of IL-4 signaling in T
cells via unknown molecular mechanisms (Inoue et al, 2007).
Consistent with these data, we report here that the loss of Dok1 and
Dok2 leads to decreased IFN-c production induced by IL-12 and
IL-18 in CD11bhigh NK cells. Similarly, impairment of cytokine-
mediated NK-cell stimulation has been also reported in SHIP1-deficient
mice (Banh et al, 2012). Dok1 and Dok2 proteins bind to SHIP1
(Mashima et al, 2009); this signaling complex has been involved in
the regulation of B- and T-cell functions (Dong et al, 2006; Yarkoni
et al, 2010). In light of these observations, it will be of interest to
investigate the potential role of this SHIP/Dok regulatory pathway
in NK-cell signaling.
Therefore, Dok1 and Dok2 differentially regulate NK-cell acti-
vation induced by activating cell surface receptors or cytokine
receptors. These differences could be due to different signaling
pathways involved downstream of activating cell surface recep-
tors and cytokine receptors (Vivier et al, 2013). To dissect the
impact of Dok1 and Dok2 on NK cell-dependent immune
responses in vivo, we challenged DKO mice using MCMV. The
control of MCMV replication was delayed in DKO as compared
Figure 5. The maturation defect of Dok1-/Dok2-deficient NK cells is a cell-intrinsic defect and is associated with increased apoptosis.
A, B WT (white circles/bars) or DKO (black circles/bars) 129/Sv (CD45.2+) cells from the bone marrow were isolated and mixed at an equal ratio with B6 (CD45.1+) cells
from the bone marrow before transfer into irradiated B6 (CD45.1+) recipients. Spleen cells from chimeric mice were isolated and analyzed 8–10 weeks after
reconstitution. NK-cell frequency within CD45.2 cells (A) and NK-cell subset distribution according to CD27 and CD11b staining in the indicated organs (B) are
shown. The data are the results of a pool of 3–4 independent experiments and are presented as mean  SD (n = 4–12, depending on the organ). ***P < 0.0001;
**P < 0.01, and *P < 0.05 (Mann–Whitney test).
C Splenocytes from WT or DKO mice are cultured in the presence or in absence of IL-15 (10 ng/ml) for at least 18 h, and cells were stained for 7-AAD and Annexin V.
Histograms corresponding to this staining in gated CD11bHigh NK-cell population from splenocytes of WT and DKO mice are shown. This experiment is
representative of three independent experiments.
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to WT mice, despite the absence of overt alteration in classically
studied markers of NK-cell antiviral responses in the spleen.
However, the proportion of mature CD11b+ NK cells was lower
in the spleen of DKO mice. Hence, it is possible that the lower
number of fully mature NK cells in DKO mice contributed to the
delay in the control of MCMV observed in these animals.
A B
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CD11b and CD11b+ NK cells differ in their expression of many
genes and therefore in several biological processes (Chiossone
et al, 2009), some of which may influence their ability to control
MCMV replication. Further studies beyond the scope of the
current manuscript will be required to identify the cause of the
delay in the control of MCMV replication in DKO mice, including
the analysis of the micro-anatomical location of NK cells in
the spleen and liver of these animals as compared to WT
controls.
In the absence of Dok1/2 proteins, NK-cell sensitivity
increases when activating receptor triggering is suboptimal. This
suggests that negative feedback loops induced by Dok proteins
in NK cells are particularly important at low level of NK-cell
activation. An attractive hypothesis would be that a weak
stimulation of an activating NK receptor could be self-controlled,
whereas a stronger stimulation would be controlled by the
engagement of inhibitory NK receptors. Additionally, signals from
activating receptors (such as BCR or TCR) in B and T cells are
controlled by Dok proteins that could avoid response to self-anti-
gen (Acuto et al, 2008; Yarkoni et al, 2010). Lymphocyte toler-
ance is also documented in NK-cell biology, where self-antigen
recognition by several activating receptors could potentially
participate to NK cell-mediated auto-reactivity (Orr & Lanier,
2010). It is tempting to speculate that Dok proteins could partici-
pate to these mechanisms of NK-cell tolerance by controlling the
threshold of NK-cell activation.
Materials and Methods
Mice and cell lines
Dok1//Dok2/ double-knockout mice (DKO mice) were
obtained by interbreeding Dok1/ mice with Dok2/ mice both
in 129/Sv background as described previously (Niki et al, 2004).
This DKO mouse strain has been backcrossed once with 129/Sv
mouse strain to generate Dok1+//Dok2+/ heterozygous double-
knockout mice (DKO+/ mice). 129/Sv and CD45.1+ C57BL/6
mouse strains were purchased from Charles River. All experiments
were performed in agreement with the French Guidelines for
animal handling and were approved by the Inserm ethical
committee. KHYG-1 NK cells (Yagita et al, 2000) were grown in
RPMI-1640 (Invitrogen) medium supplemented with 1 mM sodium
pyruvate, 100 U/ml penicillin, 100 lg/ml streptomycin, and 20%
heat-inactivated FCS plus 400 U/mL IL-2 (Roche). The K562 and
YAC-1 cell lines were cultured in RPMI-1640 containing 10%
heat-inactivated FCS with 1 mM sodium pyruvate, 100 U/ml peni-
cillin, and 100 lg/ml streptomycin.
Antibodies and reagents
The anti-mouse antibodies used for cytometry were purchased from
BD Biosciences, eBioscience and Life Technologies, and consisted of
the following: NKp46 (29A1.4), CD49b (DX5), CD11b (M1/70),
CD27 (LG.3A10, LG7.F9), KLRG-1 (2F1), CD43 (S7), CD122 (TM-
beta1), CD3 (145-2C11), TCRb (H57-597), CD19 (1D3), CD107a
(1D4B), IFN-c (XMG1.2), granzyme B (GB11). For in vitro mouse
NK-cell stimulation assays, we used purified NKp46 (2941.4),
Ly49A/D (12A8), and Ly49D (4E5) mAbs; recombinant IL-12,
IL-18, IL-15 (R&D Systems), and IL-2 (Proleukin). For human
NK-cell stimulation and analysis, we used anti-NKp30 (210845)
and anti-NKG2D (149810, R&D Systems); anti-2B4 (C1.7) and
anti-NKG2A (Z199, Beckman Coulter); and anti-IFN-c (42.15)
mAbs. Western blots were performed using Abs from Cell
Signaling Technology: ERK-1/2 (#9102), phospho-ERK-1/2
(Thr202/Thr204; #9101), AKT (#9272) and phospho-AKT
(Ser473, #4058), b-tubulin (#2128) and to immunoprecipitation
assays, anti-Dok1 (Ab8112, Abcam) and anti-Dok2 (H-12, Santa
Cruz Technology). Poly(I:C) (InvivoGen) is used for in vivo
mouse pre-activation.
Cell preparation and flow cytometry
Single-cell suspensions were prepared from spleen, inguinal lymph
nodes (iLNs), liver, bone marrow (BM), and blood from DKO and
wild-type mice. Cells were incubated with an anti-FcRcII/III mAb
(clone 2.4G2) and normal rat serum on ice for 15 min to block
the Fc receptors prior to extracellular and intracellular staining.
As DKO mice are on a 129/Sv genetic background, we used the
NKp46 marker to detect NK cells in the different tissues (CD3
NKp46+). Samples were analyzed on LSRII or FACSCalibur flow
cytometers (BD Biosciences), and data were processed using Flow-
Jo version 9.0 (TreeStar). Phosphoproteins in mouse NK cells
were detected by phosphoflow analysis (Firaguay & Nunes, 2009).
Briefly, 1.5 × 106 splenocytes were incubated with anti-NKp46
mAbs on ice for 30 min followed by incubation with goat anti-rat
F(ab’)2’ (15 lg/ml) for 3 and 5 min at 37°C. The cells were
then stained for surface markers CD3, CD122, CD49b, or NKp46
and CD11b, fixed/permeabilized with Cytofix/CytopermTM (BD
Biosciences) and indirectly intracellular stained for specific phos-
phoproteins. Ex vivo cell death in mouse NK cells was analyzed
by Annexin V and 7-AAD staining in accordance with manufac-
turer’s instructions (BD Biosciences).
Plasmids and transfection
The constructs encoding GFP-tagged full-length Dok1 or Dok2 or the
mutants lacking the PH domain, DPHDok1-GFP or DPHDok2-GFP
were described previously (Guittard et al, 2009). For overexpression
of Dok proteins, 5 × 106 KHYG-1 cells were transfected with
1.5–2 lg of plasmids by nucleofection using the Amaxa Technology
(Solution T, program Y-001; Lonza Cologne AG) (Messal et al,
2011). Transfection efficacy was quantified by flow cytometry
(> 65% GFP positive cells for all constructs).
Cell stimulation, immunoprecipitation, and immunoblotting
For receptor cross-linking experiments, KHYG-1 or NKL cells were
starved in medium 5% FCS without IL-2 for at least 20 h. Then, NK
cells were pre-incubated with NK-cell receptor agonist mAb (10 lg/
ml) on ice for 30 min, washed to eliminate the Ab overage and incu-
bated with goat anti-mouse F(ab’)2 (15 lg/ml) at 37°C for the indi-
cated times. For KHYG-1 cells expressing GFP-tagged Dok1/Dok2
proteins, the cells were starved in medium 5% FCS without IL-2
following the transfection for at least 12 h and then stimulated as
above. After stimulation, cells were lysed and post-nuclear lysates
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were incubated either with anti-GFP mAbs coupled to protein G-
Sepharose or with anti-Dok1 Abs coupled to protein A-Sepharose for
2 h at 4°C. Immunoblots were performed as previously described
(Gerard et al, 2009).
In vitro human NK-cell function
KHYG-1 cells (5 × 105 cell), expressing GFP-tagged WT Dok1/
Dok2 proteins, or mutants lacking the PH domains, were incubated
on 96-well plates precoated with anti-NKp30 mAb (2.5lg/ml) for
4 h at 37°C in the presence of brefeldin A (BD Biosciences).
KHYG-1 cells were then harvested and stained for IFN-c (mAb
PE-Cy7 conjugate) after fixation/permeabilization (BD Biosciences).
IFN-c production was measured gating on GFP+ cells by flow
cytometry.
For direct cytotoxicity assay, K562 target cells were labeled with
100 lCi of 51Cr (Amersham, Buckinghamshire, UK) for 60–90 min
at 37°C, washed three times with RPMI medium and then plated at
2,000 cells per well. Effector KHYG-1 cells, overexpressing either
Dok proteins or their mutants, were added at the indicated ratios to
triplicate wells. After 4 h of incubation at 37°C, 50 ll supernatant of
each sample was harvested and radioactivity was determined by a
gamma counter. Percent-specific lysis was calculated using standard
methods.
A B
C D
Figure 6. IFN-c production via activating receptor stimulation is increased in Dok1-/Dok2-deficient NK cells.
A, B Splenocytes from DKO or WT mice pretreated with poly(I:C) or with a PBS control were incubated on antibody-coated plates using anti-NKp46 (10 lg/ml) and anti-
Ly49D (5 lg/ml) antibodies or with IL-12 (20 ng/ml) or a mixture of IL-12 + IL-2 (3,000 U/ml) or IL-12 + IL-18 (5 ng/ml) or YAC-1 tumor cells (E:T ratio of 2:1) during
4–5 h. At the end of incubation, the splenocytes were stained for CD3, NKp46 or CD49b (DX5), and CD11b and then analyzed by flow cytometry. IFN-c expression
was determined by intracellular staining. (A) Representative flow cytometry dot plots in WT or DKO CD11b+ NK cells incubated with anti-activating receptors
antibodies are shown. (B) Histograms represent the WT or DKO NK-cell frequency  SEM corresponding to different stimulation conditions. The data are the
results of a pool of 4–5 independent experiments (n = 10–26). ***P < 0.0001; **P < 0.01, and *P < 0.05.
C Splenocytes were stimulated with plate-bound anti-NKp46 mAb at the indicated concentrations during 4–5 h. IFN-c NK production was tested by flow cytometry
gating on CD11b+ NK cells (CD3 NKp46+) from WT (white squares, dotted line) and DKO (black squares) mice. Representative data from three independent
experiments (n = 7–8 mice each genotype/ experiment; mean  SEM).
D Flow cytometry of ERK and Akt phosphorylation (Phosphoflow analysis). Splenocytes from WT (white squares, dotted line) or DKO (black squares) mice were
incubated with anti-NKp46 mAb at the indicated concentrations and stimulated with cross-linking Abs (goat anti-mouse 15 lg/ml) at 37°C for 3 min. Splenocytes
were cell surface-stained for CD3, NKp46, CD49b (DX5), and CD11b and then intracellularly stained with phosphoSer473-Akt and phospho-ERK mAbs. The results
shown represent mean Mean Fluorescence Intensity (MFI)  SEM gating on the CD11b+ NK-cell population (Supplementary Fig S3). Representative data from two
independent experiments (n = 6–7 mice each genotype/experiment). **P < 0.01 and *P < 0.05 (Mann–Whitney test).
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AB
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Figure 7. Dok1/Dok2 proteins are required to early control of MCMV infection.#
A Viral loads were tested in spleen and liver of WT (white circle) or DKO (black circle) 129/Sv mice 3 days after infection with 2 × 105 plaque-forming units (p.f.u.) of
Dm152-Rae1c MCMV inoculated intraperitoneally. Data are representative of four independent experiments (n = 5 mice per group). Horizontal line indicates the
mean of each group. *P < 0.05 (Mann–Whitney test). Viral loads were assessed by qRT-PCR (left panels) or plaque-forming assays (right panel).
B Percentage of NK cells in the lymphocyte population were measured in spleen at days 0, 1.5, 3, and 6 post-infection (left panel). Viral loads were assessed by qRT-PCR
from spleen and liver as log absolute MCMV Ie-1 RNA copy number/10 ng organ total RNA (right panels). *P < 0.05 (Mann–Whitney test).
C Percentage of NK cells in the lymphocyte population were measured in spleen at days 0, 2 and 3 post-infection (top panel), and the proportion of CD11b+ cells were
calculated from the NK subsets in spleen before (D0) and 2 or 3 days (D2, D3) post-infection (bottom panel).
D From the experiment shown in (C) percentage of IFN-c-producing NK cells were measured from spleen of WT (white bars) or DKO (black bars) mice (top panel), and
IFN-c production was evaluated by qRT-PCR from spleen of WT (white circles) or DKO (black circles) mice (bottom panel) before (D0) and 2 or 3 days (D2, D3) post-infection.
E From the experiment shown in (C), percentage of granzyme B-expressing NK cells were measured from spleen of WT (white bars) or DKO (black bars) mice
(top panel), and granzyme B production was evaluated by qRT-PCR from spleen of WT (white circles) or DKO (black circles) mice (bottom panel) before (D0) and 2 or
3 days (D2, D3) post-infection.
#Correction added on 27 June 2014, after first online publication. The correct data for liver in panel B are now shown replacing the duplicated spleen data that were
inadvertently previously shown. In the legend, all indications [(left panel)] and [(right panel)] have been corrected to reflect the Figure arrangement.
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In vitro mouse NK-cell function
Splenocytes were stimulated in 96-well plates precoated with either
anti-NKp46 or anti-Ly49D mAbs at indicated concentrations for
4–5 h at 37°C. Similar expression levels of NKp46 and Ly49D were
detected at the surface of both WT and DKO NK cells (data not
shown). For cytokine stimulation, splenocytes were incubated with
IL-12 alone or in combination with IL-12 or IL-18 at indicated
concentrations. Finally, the NK-cell reactivity was also assessed by
incubation with YAC-1 tumor cells at ratio E:T 2:1. All stimulations
were developed in the presence of monensin and brefeldin A (BD
Biosciences). Following incubation, the cells were harvested and
surface-stained with CD3, NKp46 or CD49b, CD19 and CD11b
mAbs, and then intracellular stained for IFN-c using Cytofix/Cyto-
permTM kit (BD Biosciences). In some experiments, mice were
pretreated with intraperitoneal (i.p.) injection of 150 lg poly(I:C) to
induce in vivo pre-activation of NK cells at least 14 h before
sacrifice.
Generation of mixed BM chimera
Femoral BM cells were collected from CD45.1+ C57BL/6 and
CD45.2+ Dok1/Dok2 double-knockout (DKO) 129/Sv or wild-type
(WT) 129/Sv mice and then depleted for T and B cells using rat
anti-CD3, anti-CD4, anti-CD8, and anti-CD5 mAbs, followed by
incubation with goat anti-rat IgG magnetic beads (QIAGEN).
Chimeric mice were generated by reconstituting lethally irradiated
CD45.1+ C57BL/6B6 recipient mice (500 rads × 2) with a 1:1
mixture of C57BL/6 (CD45.1+; 106 cells) and [DKO or WT 129/Sv
(CD45.2+, 106 cells)] BM cells. Eight to 10 weeks after reconstitu-
tion, spleen, liver, BM, iLNs, and blood were harvested of the
recipient mice for phenotyping (flow cytometry) and functional
tests.
MCMV infection and viral load titration
The recombinant MCMV lacking expression of the viral m152 gene
and expressing mouse NKG2D-ligand Rae-1c was generated by BAC
technology as described previously (Slavuljica et al, 2010). Mice
were infected with 2 × 105 plaque-forming units (p.f.u.) per mouse
by i.p. injection. Spleens and livers were collected 3 days after
inoculation for viral load titration by quantitative real-time PCR as
previously described (Baranek et al, 2012).
Real-time PCR experiments
RNA was reverse transcribed into cDNA with the QuantiTect reverse
transcription kit (QIAGEN), and the cDNA was analyzed by real-
time PCR using the SYBR Premix Ex Taq (Takara). Primers were as
follows: mouse Ifnc 50-CAACAGCAAGGCGAAAAAGG-30 and 50-
CCTGTGGGTTGTTGACCTCAA-30, mouse Gzmb 50-CCACTCTCGAC-
CCTACATGG-30 and 50-GGCCCCCAAAGTGACATTTATT-30, mouse Mx1
50-AGACTTGCTCTTTCTGAAAAGC-30 and 50-GACCATAGGGGTCTT-
GACCAA-30; mouse Ifnb 50-CAGTTTTGGAAGTTTCTGGTAA-30 and
50-GGTGGTCCGAGCAGAGATCTT-30, and mouse Hprt 50-GGCCCTC-
TGTGTGCTCAAG-30 and 50-CTGATAAAATCTACAGTCATAGGAAT-
GGA-30. Relative gene expression was calculated using the DDCt
method with Hprt as the endogenous control housekeeping gene.
Statistics
Data were analyzed by two-tailed non-parametric tests using Prism
software (GraphPad Software, Inc.), unless otherwise indicated. For
analysis of ≥ 3 groups, a one-way analysis of variance was used. A
P-value < 0.05 was considered significant, and the degree of
significance is indicated as follows: *, P < 0.05; **, P < 0.01; ***,
P < 0.001.
Supplementary information for this article is available online:
http://emboj.embopress.org
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